The FDA is Bringing back injectable GHK Copper Because of This! #peptides
In this presentation, the speaker outlines a body of research on the copper‑bound peptide GHK‑Cu (GHK copper). Human clinical data show that topical GHK‑Cu increases skin density and thickness and outperforms vitamin C and retinoic acid in stimulating collagen production. Animal experiments demonstrate dramatically accelerated wound healing. Cellular studies reveal that GHK‑Cu signals cells to repair DNA rather than enter senescence, and it appears to activate the longevity‑associated protein SIRT1, lowering systemic inflammation markers such as IL‑6. Additional work shows GHK‑Cu can rejuvenate hair follicles when delivered in a serum. On the regulatory front, the FDA is removing GHK‑Cu from its “do‑not‑compound” peptide ban and is evaluating the peptide for COPD and emphysema, targeting its ability to down‑regulate excessive collagen that causes lung fibrosis—a condition with few effective treatments. Overall, the speaker presents a compelling case that GHK‑Cu has broad therapeutic potential across dermatology, wound care, respiratory disease, and anti‑aging domains.
